Lupus & antiphospholipid syndrome
Progression of atherosclerotic plaques over 3 years in patients with systemic lupus erythematosus is inversely associated with continuous hydroxychloroquine treatment
Main finding · Atherosclerotic plaque progressionResult — go to the resultB −2.5Authors' conclusion
Despite quiescent disease state, atherosclerosis progresses over time in patients with SLE.
Study context
- Population
- Well-characterized patients with systemic lupus erythematosus (SLE) assessed twice, 3 years apart, with high-frequency ultrasound (HFUS) for intima-media thickness (IMT) and atherosclerotic plaques50 females
- Participants
- 57 patients
- Exposure
- Hydroxychloroquine use vs no hydroxychloroquine at follow-up
- Outcome
- Atherosclerotic plaque progression (predictors)
- Follow-up
- 3 years
Methodological details3-year follow-up, multivariable logistic regression
- 3-year follow-up
- Multivariable logistic regression
Main finding
Atherosclerotic plaque progression · 3 year follow-up
B
−2.5
P = 0.047
As reported in the abstract
- Plaque progression
- 27 (47.4%)
- Atherosclerotic plaques at follow-up
- 29/57 (50.9%)
Observational data: associations, not effects.
Further findings
Common carotid IMT in patients with plaque progression · 3 year follow-up
- IMT increased significantly in patients with plaque progression
- P = 0.04
OxyP vs plaque progression or damage accrual
- OxyP not significantly associated with plaque progression or damage accrual
Original publication
Progression of atherosclerotic plaques over 3 years in patients with systemic lupus erythematosus is inversely associated with continuous hydroxychloroquine treatment. Scand J Rheumatol. Published 5 November 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →